Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy 1st SBFM Trading Day of 2023. Looking for better days, weeks and months ahead!
Happy 1st CCAJ Trading Day of 2023. Looking for better days, weeks and months ahead!
Interesting rumor, but I'm not sure we have heard the last of the PLpro anti-Coronavirus mice trials from the University of Arizona or the upcoming K1.1-LNP xenograft mice in vivo cancer trials in March 2023.
Nonetheless, the RS has clearly failed. Had the PPS stayed above $4 (or even $2) in 2022 I might have thought otherwise. If it gets back to $2-4+ in 2023 then I'll have different thoughts on this!
Who knows what type of PR will come out, but it will likely be related to progress on the SBFM topics below:
July 2022: expanded collaboration with the University of Arizona to accelerate the development of our novel PLpro inhibitors for our anti-Coronavirus treatment program.
October 2022: acquired Canadian generic pharmaceuticals company, Nora Pharma Inc., with sales of approximately $14 million. Sunshine Biopharma now has over 50 generic prescription drugs on the market in Canada with plans to grow further throughout North America and potentially other markets around the world.
November 2022: vigorously pushed forward with our oncology K1.1 mRNA development program by entering into a key collaboration arrangement with a leading lipid nano-particle (LNP) formulation company in North America. Beginning in March, 2023, our partner generated K1.1-LNP formulations will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials.
2023: objectives going forward will be focused on achieving profitability and investing in our proprietary drug development program.
Hoping that is the case for 2023! I'm just highlighting the 52-week range from $.09 to $.008 and where it ended yesterday. Good companies should increase value if I'm not mistaken!
Our bags may be full of coal now, but 2023 may be the year that SBFM turns it into gold. Check back in 6 months and we'll chat again.
0 trading days left until 2023 and the end of 2022 was not good for AXXA shareholders (except today's gain). Let's see if the management can come into 2023 with a new strategy that rewards vs. punishes existing shareholders.
0 trading days left until 2023 and the end of 2022 was not good for SBFM shareholders. Let's see if the management can come into 2023 with a new strategy that rewards vs. punishes existing shareholders.
0 trading days left until 2023 and the end of 2022 was not good for CCAJ shareholders. Let's see if the management can come into 2023 with a new strategy that rewards vs. punishes existing shareholders.
I keep seeing FDA Acceptance of IND Application PRs for biopharma companies so perhaps that will be the excitement in 2023 for SBFM. Stock prices seem to go up between 100-300% for those announcements. Time to get the ball rolling!
Below is one example:
https://ih.advfn.com/stock-market/NASDAQ/hoth-therapeutics-HOTH/stock-news/89873816/hoth-therapeutics-announces-fda-acceptance-of-ind
2 more trading days until AXXA starts a new year of trading in 2023! Looking forward to some new found excitement and momentum throughout the new year.
2 more trading days until SBFM starts a new year of trading in 2023! Looking forward to some new found excitement and momentum throughout the new year.
2 more trading days until CCAJ starts a new year of trading in 2023! Looking forward to some new found excitement and momentum throughout the new year.
And to All Good Luck in 2023!
4 trading days left in 2022. Unfortunately 2022 did not go as expected. Not expecting much next week, but hopefully AXXA can generate some unexpected excitement early in 2023.
4 trading days left in 2022. Unfortunately 2022 did not go as expected. Not expecting much next week, but hopefully SBFM can generate some unexpected excitement early in 2023.
4 trading days left in 2022. Unfortunately 2022 did not go as expected. Not expecting much next week, but hopefully CCAJ can generate some unexpected excitement early in 2023.
From MAY 2022 article: "Now, the company is manufacturing 5 kilograms (11 pounds) of the compound in preparation for another investigational new drug (IND) study. With the data from that upcoming IND study, on top of its existing preclinical results, Sunshine hopes to fast-track the drug candidate for clinical trials at McGill University’s Jewish General Hospital."
Simply need an update on the "upcoming IND study."
"2022 has been a transformative year for the Company despite some challenging headwinds with the economy and financial markets."
Here's an abbreviated summary from today's Annual Shareholders Letter:
February-April 2022: received $40M+ from multiple offerings
April 2022: announced biopharma pipeline developments for mRNA molecules capable of destroying multidrug resistant cancer cells grown in culture. These mRNA molecules bear the laboratory designation K1.1.
July 2022: expanded collaboration with the University of Arizona to accelerate the development of our novel PLpro inhibitors for our anti-Coronavirus treatment program.
October 2022: acquired Canadian generic pharmaceuticals company, Nora Pharma Inc., with sales of approximately $14 million. Sunshine Biopharma now has over 50 generic prescription drugs on the market in Canada with plans to grow further throughout North America and potentially other markets around the world.
November 2022: vigorously pushed forward with our oncology K1.1 mRNA development program by entering into a key collaboration arrangement with a leading lipid nano-particle (LNP) formulation company in North America. Beginning in March, 2023, our partner generated K1.1-LNP formulations will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials.
2023: objectives going forward will be focused on achieving profitability and investing in our proprietary drug development program.
Why does CCAJ have 3 different Securities Counsels? Do they need that many for all the new corporate work they are doing or something else? They are in Las Vegas, West Hollywood and Houston. Just curious when looking at their profile again.
Scroll down here: https://www.otcmarkets.com/stock/CCAJ/profile
Yes, but a new Director of Operations: Amélie Fournier
Unless I missed a prior announcement this is a new person who has joined SBFM. Perhaps that is what they needed, along with Nora Pharma and $40M (now $22M) to make some significant progress in 2023. It will be a new year, so perhaps a new start to move this stock from $.70 to $7.00 to $70. That only requires moving the decimal point one then two positions to the right! Anything is possible, right?
Looks like they got the notice on December 6th so they have until June 5th to meet the minimum bid requirement. If they can't do it by then they may get another extension (see criteria below). Nonetheless, Nora Pharma needs to get busy to bolster up SBFM with some excellent news about how much more revenue they will be generating and the timeline for the Biosimilar getting approval at least by Health Canada. Then they need to expand into the US as soon as possible and add the SBFM anti-cancer treatment. Six months isn't a long time, but should be enough to get some headlines that have substance.
From the recent SEC filing Form 8K: Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 6, 2022, Sunshine Biopharma, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immediate effect on the listing of the Company’s common stock. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from December 6, 2022, or until June 5, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before June 5, 2023, the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement. The notification letter also disclosed that in the event the Company does not regain compliance with the Minimum Bid Price Requirement by June 5, 2023, the Company may be eligible for additional time. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. However, if it appears to the staff of Nasdaq (the “Staff”) that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that its securities will be subject to delisting.
The Company intends to continue actively monitoring the bid price for its common stock between now and June 5, 2023 and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.
Did you know: In August 2021, Nora Pharma, a Canadian pharmaceutical company, entered into an exclusive agreement with a biopharmaceutical partner to acquire the commercial rights to a biosimilar drug. ”This announcement marks the culmination of a major shift for our business. Over the past 12 months, we have made a significant change in our activities, moving from the private generic sector exclusively in Quebec to a national company with a drug portfolio that will double in size over the next three years. Our announcement today will also support the objective of both private insurers and public formularies to reduce the costs of acquiring biosimilars. It also sends a powerful signal of our ambition to become a key player in the Canadian pharmaceutical landscape. Finally, the addition of a biosimilar drug to our portfolio will create new job opportunities within the organization, in addition to accelerating the growth and competitiveness of the company. ” – Malek Chamoun, president
It appears the Biosimilar drug market is expanding. Saw this today about Biogen:
14:34 ET -- Biogen Inc. is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The company said the U.S. Food and Drug Administration has accepted for review the abbreviated Biologics License Application for BIIB800, a proposed biosimilar to Roche Holdings AG anti-inflammatory drug Actemra. In September, the European Medicines Agency accepted a BIIB800 Marketing Authorization Application for review. Biogen previously reported data from a Phase 3 trial demonstrating equivalent efficacy and comparable safety and immunogenicity profile.
More here about the FDA and Biosimilars: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
We'll see. They need to release the timeline and then some pictures of the luxury homes and high rise under construction. That would provide a bit of realness to this company.
I read all the FAQs and rationale and risks written by CEO Pitre and still not making complete sense to me that they should be doing this. The letter did acknowledge that "Prior to effectuation of the Reverse Split, the Board reserves the right to elect to abandon the Reverse Split if it determines, in its sole discretion, that the Reverse Split is no longer in the best interests of the Company and its stockholders" so we'll see what they do because so far making the announcement and now providing more details isn't working. They keep saying in the "long term" but not saying if that is months or years.
Sounds good. Add a company buyback and the AXXA price should make significant gains.
A company buyback would be good. It would also show they know the theory of supply vs. demand and the impact on price.
Well, with $40,000,000 they should be able to create more confidence that the science is finally leading to a marketable new drug! What happened with the 2012 science? Where is the advancement? Why haven't they moved beyond mice studies in the past 10 years? Did they need $40M to do something they couldn't do for the past 10 years? If they could make a better case for advancement in their science, confidence in the company would follow. It is very clear that the shareholder confidence they had last year has been lost this year despite the funding - that's my point!
Will they turnaround? I think that will be much clearer in a few more months so I'm sitting tight despite the low confidence today.
Only worried to the extent that SBFM management had $40,000,000+ to make something of this company and it's drugs, yet they don't seem to be able to use it effectively to generate confidence in the company and the associated PPS. I know they bought Nora Pharma but so far that hasn't created any confidence or increase in PPS. Seems they need to say specifically what they are going to do with the remaining funds to bring the drugs to market. For example, hire someone who has a pattern of success in doing just that - recruit someone from Moderna with those remaining millions!
You say: "Anytime insiders buy into their entity or livelyhood-I'm bullish-not interested in anyone's "opinions"". Well, why would an insider buy into their livelihood and then announce a R/S that causes a 70% decline in their livelihood? Still not making sense!
If you can make sense out of this, let me know.
How many more days until SBFM gets the NAS notice of non-compliance?
So "Coastal Capital Acquisition Corporation believes it is placed precisely, in terms of long-term growth and stability, and looks toward the future endeavors of the company. By effecting the Reverse Stock Split, it will make available more equity for Strategic Partnerships in addition with financing options and acquisitions which we believe will be in the best interest of the shareholders and the company."
Was it placed "precisely" and "in the best interest of shareholders" to make the PPS drop sharply in 1 day? Seems like CCAJ management either didn't know what they were doing, misspoke about their intentions, or have a scheme in the making. Only time will tell!
Darn! I thought this would be a winner with a cancer and covid treatment (and amino acids)!
Haven't they been saying it is only 12-18 more months to develop these treatments? That is not long in drug development terms.
I'm not new, but guess I'm stuck here below $1 for awhile longer!
Even nicer...$.005!
Yes, was here for the quick rise to $.022 so also thinking that is achievable again relatively soon (1-2 months). After that, how high CCAJ can go is a mystery to me!
Here's one LNP company...not sure if this is the one that SBFM is working with, but interesting nonetheless...
https://mrna.creative-biolabs.com/lipid-nanoparticle.htm?gclid=Cj0KCQiA4OybBhCzARIsAIcfn9nHBckzuhftVM1rukj-De1UVUWhJtsEilAndQ-kUiMUZ8ytRnKoQesaAnrcEALw_wcB
I see there are several Lipid Nanoparticle (LNP) companies out there including Moderna. It will be interesting once we find out which company they are working with.
$0.25 seems a bit high for this little company so how about $0.02 by early 2023?
Perhaps there is a hidden message in this PR. It could be that they are going to be doing never-ending mice studies or it could be that they are on the verge of a breakthrough. Should know the answer in 2023!
What are your projections for the remainder of 2022 and then 2023?